Intravenous immunoglobulin therapy for Miller Fisher syndrome.
Autor(es): Mori Masahiro,Kuwabara Satoshi,Fukutake Toshio,Hattori Takamichi
Resumo: We analyzed clinical recovery of 92 patients with Miller Fisher syndrome who had been treated with IV immunoglobulin (IVIg; n = 28), plasmapheresis (n = 23), and no immune treatment (n = 41). IVIg slightly hastened the amelioration of ophthalmoplegia and ataxia, but the times of the disappearances of those symptoms were similar among three groups. In Miller Fisher syndrome, IVIg and plasmapheresis seem not to have influenced patients' outcomes, presumably because of good natural recovery.
Imprenta: Neurology, v. 68, n. 14, p. 1144-1146, 2007
Identificador do objeto digital: 10.1212/01.wnl.0000258673.31824.61
Descritores: Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Antibodies ; Guillain-Barre Syndrome - Public health
Data de publicação: 2007
